Reference(s)
Click here to return to the Reference Table

Category: Carcinomas
Cancer type: Lung
Descriptor: Reviews


Reference Number: 740
Toschi L, Cappuzzo F. Clinical implications of MET gene copy number in lung cancer. Future Oncol. 6, 239-47 (2010)
PubMed link      E-mail link

Reference Number: 741
Lawrence RE, Salgia R. MET molecular mechanisms and therapies in lung cancer. Cell Adh Migr. 4, 146-52 (2010)
PubMed link      E-mail link

Reference Number: 756
Cipriani NA, Abidoye OO, Vokes E, Salgia R. MET as a target for treatment of chest tumors. Lung Cancer. 63, 169-79 (2009)
PubMed link      E-mail link

Reference Number: 790
Jafri NF, Ma PC, Maulik G, Salgia R. Mechanisms of metastasis as related to receptor tyrosine kinases in small-cell lung cancer. J Environ Pathol Toxicol Oncol. 22, 147-65 (2003)
PubMed link      E-mail link

Reference Number: 794
Maulik G, Kijima T, Salgia R. Role of receptor tyrosine kinases in lung cancer. Methods Mol Med. 74, 113-25 (2003)
PubMed link      E-mail link

Reference Number: 879
Wang X, Li K, Chen H, Wang D, Zhang Y, Bai C. Does hepatocyte growth factor/c-Met signal play synergetic role in lung cancer? J Cell Mol Med. 14, 833-9 (2010)
PubMed link      E-mail link

Reference Number: 958
Rodig SJ, Shapiro GI. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr Opin Investig Drugs. 11, 1477-90 (2010)
PubMed link      E-mail link

Reference Number: 973
Bonanno L, Jirillo A, Favaretto A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors and new therapeutic perspectives in non small cell lung cancer. Curr Drug Targets. 12, 922-33 (2011)
PubMed link      E-mail link

Reference Number: 1007
Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res. 15, 2207-14 (2009)
PubMed link      E-mail link

Reference Number: 1180
Ruppert AM, Beau-Faller M, Belmont L, Lavolé A, Gounant V, Cadranel J, Wislez M. [A simple view on lung cancer biology: the MET pathway]. Rev Mal Respir. 28, 1241-9 (2011)
PubMed link      E-mail link

Reference Number: 1192
Belalcazar A, Azaña D, Perez CA, Raez LE, Santos ES. Targeting the Met pathway in lung cancer. Expert Rev Anticancer Ther. 12, 519-28 (2012)
PubMed link      E-mail link

Reference Number: 1264
Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Biological agents alone or in combination as second-line therapy in advanced non-small-cell lung cancer: systematic review of randomized studies. Expert Rev Anticancer Ther. 12, 1299-312 (2012)
PubMed link      E-mail link

Reference Number: 1332
Suda K, Mizuuchi H, Maehara Y, Mitsudomi T. Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny. Cancer Metastasis Rev. 31, 807-14 (2012)
PubMed link      E-mail link

Reference Number: 1356
Alamgeer M1, Ganju V, Watkins DN. Novel therapeutic targets in non-small cell lung cancer. Curr Opin Pharmacol. 13, 394-401 (2013)
PubMed link      E-mail link

Reference Number: 1416
Gridelli C1, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F. ALK inhibitors in the treatment of advanced NSCLC. Cancer Treat Rev. 40, 300-6 (2014)
PubMed link      E-mail link

Reference Number: 1497
Robinson KW, Sandler AB. The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents. Oncologist. 18, 115-22 (2013)
PubMed link      E-mail link

Reference Number: 1538
Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, Tiseo M. Targeting the MET gene for the treatment of non-small-cell lung cancer. Crit Rev Oncol Hematol. 89, 284-99 (2014)
PubMed link      E-mail link

Reference Number: 1574
Frampton JE. Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer. Drugs. 73, 2031-51 (2013)
PubMed link      E-mail link

Reference Number: 1637
Capelletti M, Gelsomino F, Tiseo M. MET and ALK as targets for the treatment of NSCLC. Curr Pharm Des. 20, 3914-32 (2014)
PubMed link      E-mail link

Reference Number: 1678
Dimou A, Non L, Chae YK, Tester WJ, Syrigos KN. MET gene copy number predicts worse overall survival in patients with non-small cell lung cancer (NSCLC); a systematic review and meta-analysis. PLoS One. 9, e107677 (2014)
PubMed link      E-mail link

Reference Number: 1687
Gozdzik-Spychalska J, Szyszka-Barth K, Spychalski L, Ramlau K, Wójtowicz J, Batura-Gabryel H, Ramlau R. C-MET inhibitors in the treatment of lung cancer. Curr Treat Options Oncol. 15, 670-82 (2014)
PubMed link      E-mail link

Reference Number: 1716
Nurwidya F, Takahashi F, Murakami A, Kobayashi I, Kato M, Shukuya T, Tajima K, Shimada N, Takahashi K Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Respir Investig. 52, 82-91 (2014)
PubMed link      E-mail link

Reference Number: 1757
Passiglia F, Van Der Steen N, Raez L, Pauwels P, Gil-Bazo I, Santos E, Santini D, Tesoriere G, Russo A, Bronte G, Zwaenepoel K, Cappuzzo F, Rolfo C The role of cMet in non-small cell lung cancer resistant to EGFR-inhibitors: did we really find the target? Curr Drug Targets. 15, 1284-92 (2014)
PubMed link      E-mail link

Reference Number: 1819
Pérez-Ramírez C, Cañadas-Garre M, Jiménez-Varo E, Faus-Dáder MJ, Calleja-Hernández MÁ. MET: a new promising biomarker in non-small-cell lung carcinoma. Pharmacogenomics. 16, 631-47 (2015)
PubMed link      E-mail link

Reference Number: 1821
Li A, Gao HF, Wu YL. Targeting the MET pathway for potential treatment of NSCLC. Expert Opin Ther Targets. 19, 663-74 (2015)
PubMed link      E-mail link

Reference Number: 1835
Loong HH, Mok K, Leung LK, Mok TS. Crizotinib in the management of advanced-stage non-small-cell lung cancer. Future Oncol. 11, 735-45 (2015)
PubMed link      E-mail link

Reference Number: 1843
Rolfo C, Van Der Steen N, Pauwels P, Cappuzzo F. Onartuzumab in lung cancer: the fall of Icarus? Expert Rev Anticancer Ther. 15, 487-9 (2015)
PubMed link      E-mail link